The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development ...

AI in drug discovery offers key market opportunities by enhancing drug development efficiency, reducing costs, and improving success rates. It supports personalized medicine, facilitating custom ...

AI and machine learning are revolutionizing drug discovery, development, and lifecycle management, addressing industry ...

Quick Read Eli Lilly (LLY) and Nvidia (NVDA) will invest up to $1B over five years in an AI drug discovery lab. AI could ...

Nvidia and Eli Lilly are teaming up on a $1 billion AI-powered lab to accelerate drug discovery, combining robotics, molecular modeling and automated research workflows.

For decades, the process of drug discovery has been a prolonged, costly, and unpredictable endeavor — an effort that ...

Nvidia is turning its AI firepower toward the hardest problems in medicine, striking multibillion-dollar alliances with ...

Explore the role of transcription factor biology in drug discovery and how it impacts our understanding of disease mechanisms ...

Join us at HIMSS26, the premier event that brings together healthcare professionals, technology partners, policymakers and thought leaders for four days of learning, collaboration and inspiration.

Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years ...

The partnership between Nvidia and Eli Lilly is not just about financial investment; it represents a new blueprint for how drugs will be developed in the future. By combining their resources and ...

A biotech which seeks to accelerate drug discovery by providing easy access to functional proteins through its proprietary platform has extended its total Series C funding to £64.5m.